Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inspire Medical Systems (INSP) Cash & Equivalents (2017 - 2025)

Historic Cash & Equivalents for Inspire Medical Systems (INSP) over the last 9 years, with Q4 2025 value amounting to $104.8 million.

  • Inspire Medical Systems' Cash & Equivalents fell 3019.45% to $104.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $104.8 million, marking a year-over-year decrease of 3019.45%. This contributed to the annual value of $104.8 million for FY2025, which is 3019.45% down from last year.
  • According to the latest figures from Q4 2025, Inspire Medical Systems' Cash & Equivalents is $104.8 million, which was down 3019.45% from $112.8 million recorded in Q3 2025.
  • Over the past 5 years, Inspire Medical Systems' Cash & Equivalents peaked at $467.1 million during Q2 2023, and registered a low of $53.9 million during Q1 2025.
  • Its 5-year average for Cash & Equivalents is $224.9 million, with a median of $186.1 million in 2022.
  • In the last 5 years, Inspire Medical Systems' Cash & Equivalents skyrocketed by 15033.55% in 2023 and then plummeted by 6928.33% in 2025.
  • Inspire Medical Systems' Cash & Equivalents (Quarter) stood at $214.5 million in 2021, then surged by 105.9% to $441.6 million in 2022, then crashed by 57.98% to $185.5 million in 2023, then decreased by 19.07% to $150.2 million in 2024, then plummeted by 30.19% to $104.8 million in 2025.
  • Its last three reported values are $104.8 million in Q4 2025, $112.8 million for Q3 2025, and $106.9 million during Q2 2025.